CA2304961A1 - Procedes et compositions utilises pour lier des cellules souches hematopoietiques - Google Patents
Procedes et compositions utilises pour lier des cellules souches hematopoietiques Download PDFInfo
- Publication number
- CA2304961A1 CA2304961A1 CA002304961A CA2304961A CA2304961A1 CA 2304961 A1 CA2304961 A1 CA 2304961A1 CA 002304961 A CA002304961 A CA 002304961A CA 2304961 A CA2304961 A CA 2304961A CA 2304961 A1 CA2304961 A1 CA 2304961A1
- Authority
- CA
- Canada
- Prior art keywords
- binding partner
- stem cells
- lectin
- cells
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000027455 binding Effects 0.000 title claims abstract description 157
- 238000000034 method Methods 0.000 title claims abstract description 69
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title abstract description 10
- 210000000130 stem cell Anatomy 0.000 claims abstract description 41
- 238000000746 purification Methods 0.000 claims abstract description 10
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 8
- 230000008685 targeting Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 84
- 150000001720 carbohydrates Chemical group 0.000 claims description 48
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 108090001090 Lectins Proteins 0.000 claims description 33
- 102000004856 Lectins Human genes 0.000 claims description 33
- 239000002523 lectin Substances 0.000 claims description 33
- 239000007787 solid Substances 0.000 claims description 21
- 239000012472 biological sample Substances 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 11
- 229940060155 neuac Drugs 0.000 claims description 10
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 230000003100 immobilizing effect Effects 0.000 claims description 8
- 210000004700 fetal blood Anatomy 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 108010089814 Plant Lectins Proteins 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 239000003726 plant lectin Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 5
- 241001521394 Maackia amurensis Species 0.000 claims description 4
- 240000006028 Sambucus nigra Species 0.000 claims description 3
- 235000003142 Sambucus nigra Nutrition 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- 241000209140 Triticum Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000008995 european elder Nutrition 0.000 claims description 3
- 108010014765 tomato lectin Proteins 0.000 claims description 3
- 108010046569 Galectins Proteins 0.000 claims description 2
- 102000007563 Galectins Human genes 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 229940037467 helicobacter pylori Drugs 0.000 claims description 2
- 239000012510 hollow fiber Substances 0.000 claims description 2
- 231100000167 toxic agent Toxicity 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 239000003440 toxic substance Substances 0.000 claims 1
- PNIWLNAGKUGXDO-LNCRCTFVSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r)-5-amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 PNIWLNAGKUGXDO-LNCRCTFVSA-N 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 abstract description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 17
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 17
- 108090000288 Glycoproteins Proteins 0.000 description 14
- 102000003886 Glycoproteins Human genes 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 229940098773 bovine serum albumin Drugs 0.000 description 13
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000011534 incubation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 230000009918 complex formation Effects 0.000 description 7
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 101150052863 THY1 gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000010897 colon adenocarcinoma Diseases 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 description 2
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 description 2
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 102000003838 Sialyltransferases Human genes 0.000 description 2
- 108090000141 Sialyltransferases Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 240000003864 Ulex europaeus Species 0.000 description 2
- 235000010730 Ulex europaeus Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- -1 aminophenylene diamine Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006853 reporter group Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- LNPMZQXEPNWCMG-UHFFFAOYSA-N 4-(2-aminoethyl)aniline Chemical compound NCCC1=CC=C(N)C=C1 LNPMZQXEPNWCMG-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000013925 CD34 antigen Human genes 0.000 description 1
- 108050003733 CD34 antigen Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001669680 Dormitator maculatus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- PNIWLNAGKUGXDO-UHFFFAOYSA-N Lactosamine Natural products OC1C(N)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 PNIWLNAGKUGXDO-UHFFFAOYSA-N 0.000 description 1
- 241000227653 Lycopersicon Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 1
- 102000001558 Sialic Acid Binding Ig-like Lectin 1 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000492514 Tetragonolobus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 1
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 1
- DOVBXGDYENZJBJ-ONMPCKGSSA-N lactosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DOVBXGDYENZJBJ-ONMPCKGSSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- MPXAYYWSDIKNTP-UHFFFAOYSA-N n-(2-aminophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC=C1N MPXAYYWSDIKNTP-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010004486 trans-sialidase Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne des procédés et des compositions utilisés pour lier des cellules souches hématopoïétiques. Les procédés de l'invention consistent généralement à utiliser un partenaire de liaison qui forme un complexe avec une structure à base de lactosamine syalylée présente sur la surface des cellules souches. La formation desdits complexes facilite, par exemple, l'immobilisation, la purification, l'identification et le ciblage de cellules souches hématopoïétiques. Lesdites compositions de l'invention comprennent généralement un partenaire de liaison qui peut être libre, fixé à un matériau de support ou lié à un agent marqueur ou thérapeutique.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5997297P | 1997-09-25 | 1997-09-25 | |
| US60/059,972 | 1997-09-25 | ||
| PCT/US1998/020063 WO1999015628A1 (fr) | 1997-09-25 | 1998-09-24 | Procedes et compositions utilises pour lier des cellules souches hematopoietiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2304961A1 true CA2304961A1 (fr) | 1999-04-01 |
Family
ID=22026508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002304961A Abandoned CA2304961A1 (fr) | 1997-09-25 | 1998-09-24 | Procedes et compositions utilises pour lier des cellules souches hematopoietiques |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1017790A1 (fr) |
| JP (1) | JP2001517427A (fr) |
| CN (1) | CN1280611A (fr) |
| AU (1) | AU9508998A (fr) |
| CA (1) | CA2304961A1 (fr) |
| WO (1) | WO1999015628A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE307881T1 (de) | 1999-03-30 | 2005-11-15 | Netech Inc | Methode zur selektiven trennung von blutzellen unter verwendung von lektin |
| AU2001277635A1 (en) * | 2000-03-14 | 2001-10-08 | Exiqon A/S | New methods for separation and isolation of subpopulations of cells in biological samples |
| JP4703943B2 (ja) * | 2000-11-15 | 2011-06-15 | 幸夫 加藤 | 外部刺激に対する抵抗性付与剤 |
| EP1613742A2 (fr) * | 2003-04-08 | 2006-01-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Cellules souches presentant une sensibilite accrue a un agent chimio-attractif, methodes de production et d'utilisation associees |
| WO2007006870A2 (fr) * | 2005-07-11 | 2007-01-18 | Suomen Punainen Risti, Veripalvelu | Nouvelles compositions a profil glucidique issues de cellules souches et methodes d'analyse et de modification de ces compositions |
| WO2007054622A1 (fr) * | 2005-11-08 | 2007-05-18 | Suomen Punainen Risti, Veripalvelu | Nouvelles compositions a profils glucidiques tirees de cellules humaines et procedes d'analyse et de modification correspondants |
| CA2692445A1 (fr) * | 2006-06-29 | 2008-01-03 | Glykos Finland Oy | Nouvelles compositions de glycane cellulaire |
| KR20080037883A (ko) * | 2006-10-27 | 2008-05-02 | 세원셀론텍(주) | 메디컬 키트 및 이의 사용방법 |
| EP2108043A4 (fr) * | 2007-01-18 | 2010-04-21 | Suomen Punainen Risti Veripalv | Nouveaux procedes et reactifs pour la production de cellules |
| EP2115460A4 (fr) * | 2007-01-18 | 2010-01-13 | Suomen Punainen Risti Veripalv | Nouveaux glucides issus de cellules humaines et methodes d'analyse et de modification |
| PL2718416T3 (pl) * | 2011-06-06 | 2020-05-18 | ReGenesys BVBA | Namnażanie komórek macierzystych w bioreaktorach włóknisto-kapilarnych |
| CN103087980A (zh) * | 2011-10-28 | 2013-05-08 | 卢磊磊 | 凝集素用于识别、纯化干细胞的方法、试剂盒及应用方法 |
| CN103087978A (zh) * | 2011-10-28 | 2013-05-08 | 卢磊磊 | 从造血器官、血液中获得干细胞的试剂盒及其应用方法 |
| KR20150023297A (ko) * | 2012-05-31 | 2015-03-05 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 고상 우레이드에 대한 생물학적 표적의 선택적 결합 |
| JP6057574B2 (ja) * | 2012-07-11 | 2017-01-11 | キヤノン株式会社 | 造血幹細胞識別用プローブ |
| JP2019503985A (ja) * | 2015-11-03 | 2019-02-14 | グリコミメティクス， インコーポレイテッド | モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法 |
| US12319749B2 (en) | 2019-02-01 | 2025-06-03 | Sumitomo Chemical Company, Limited | Antibody and functional fragment thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5227160A (en) * | 1988-07-15 | 1993-07-13 | The Biomembrane Institute | Monoclonal antibody nuh2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen |
| IL106255A0 (en) * | 1993-04-23 | 1993-11-15 | Baxter Int | Method for isolating human blood cells |
-
1998
- 1998-09-24 AU AU95089/98A patent/AU9508998A/en not_active Abandoned
- 1998-09-24 CN CN98811483.6A patent/CN1280611A/zh active Pending
- 1998-09-24 EP EP98948540A patent/EP1017790A1/fr not_active Withdrawn
- 1998-09-24 WO PCT/US1998/020063 patent/WO1999015628A1/fr not_active Ceased
- 1998-09-24 JP JP2000512922A patent/JP2001517427A/ja not_active Withdrawn
- 1998-09-24 CA CA002304961A patent/CA2304961A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1280611A (zh) | 2001-01-17 |
| JP2001517427A (ja) | 2001-10-09 |
| EP1017790A1 (fr) | 2000-07-12 |
| WO1999015628A1 (fr) | 1999-04-01 |
| AU9508998A (en) | 1999-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wilchek et al. | The avidin-biotin complex in immunology | |
| CA2304961A1 (fr) | Procedes et compositions utilises pour lier des cellules souches hematopoietiques | |
| US6362010B1 (en) | Methods and compositions for release of CD3430 cells from affinity matrices | |
| JPS59180362A (ja) | 免疫定量法における抗イデイオタイプ抗体の使用 | |
| JPH10507997A (ja) | Ｔ細胞の活性化および増殖を誘導するための抗ｃｄ３抗体−アミノデキストラン結合体 | |
| Karsten et al. | A New Monoclonal Antibody (A78-G/A7) to the Thomsen—Friedenreich Pan-Tumor Antigen | |
| US5356779A (en) | Assay for direct binding of peptides that are T-cell epitopes to MHC gene products on intact antigen-presenting cells and the use thereof for screening susceptibility of autoimmune diseases | |
| CA1340311C (fr) | Depistage d'anticorps se liant aux epitopes glucidiques d'antigenes associes a des tumeurs; applications | |
| Coombe et al. | Particle recognition by haemocytes from the colonial ascidian Botrylloides leachii: Evidence that the B. leachii HA-2 agglutinin is opsonic | |
| WO1986002364A1 (fr) | Anticorps monoclonaux et leur utilisation | |
| Thorpe et al. | Cold agglutinin activity is common among human monoclonal IgM Rh system antibodies using the V4‐34 heavy chain variable gene segment | |
| US5786160A (en) | Natural killer cell-specific antigen and antibodies that identify the same | |
| Wright | [7] Methods for the study of receptor-mediated phagocytosis | |
| US5034515A (en) | Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use | |
| JP2010156699A (ja) | ヤドリギレクチンに対する個体の応答性を判定する方法 | |
| Suzuta | Therapeutic and diagnostic applications of latex-bound immunoglobulins | |
| JPH06504670A (ja) | 微生物に関する脂質レセプター及び対応の付着因子、付着因子をコードするｄｎａ配列、並びにそれらの利用方法 | |
| JPH04501352A (ja) | ナチュラルキラー細胞および非特異的細胞障害性細胞レセプターに対する抗体 | |
| JP2008195666A (ja) | ２−６シアリル６−スルホ糖鎖に対する抗体 | |
| Pendu et al. | Expression of ABH, Lewis and related tissue antigens in the human thymus | |
| Taki et al. | Purification of anti-glycosphingolipid antibody and topological localization of glycosphingolipid on the cell surface of rat ascites hepatomas | |
| KR890001538B1 (ko) | 세포기능 조절물질 등을 결합시킨 보체성분 Clq의 제조법 및 이 보체성분 Clq을 사용하는 측정법 | |
| JP3036545B2 (ja) | モノクローナル抗体とこれを産生するハイブリドーマ細胞株、およびこれを用いる免疫学的測定法 | |
| JPS63258493A (ja) | 抗ガングリオシドｇｍ↓１単クロ−ン性抗体、これを産生する細胞及びこれから成る試薬 | |
| CA1314246C (fr) | Anticorps monoclonal (mz) anti-ganglioside gd -, cellules produisant cet anticorps monoclonal et reactif le contenant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |